Healthcare provider profile · identity verified

Michael A Hoffmann, M.D.

Internal Medicine · BATESVILLE, IN · NPI 1629058037

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	242	82
Levothyroxine Sodium	Levothyroxine Sodium	221	57
Rosuvastatin Calcium	Rosuvastatin Calcium	209	71
Lisinopril	Lisinopril	192	57
Losartan Potassium	Losartan Potassium	187	57
Omeprazole	Omeprazole	178	58
Gabapentin	Gabapentin	177	53
Amlodipine Besylate	Amlodipine Besylate	175	61
Metoprolol Succinate	Metoprolol Succinate	151	47
Eliquis	Apixaban	137	28
Spironolactone	Spironolactone	133	47
Carvedilol	Carvedilol	113	32
Duloxetine Hcl	Duloxetine Hcl	112	28
Sertraline Hcl	Sertraline Hcl	100	26
Tramadol Hcl	Tramadol Hcl	97	22
Trazodone Hcl	Trazodone Hcl	94	34
Pregabalin	Pregabalin	93	21
Potassium Chloride	Potassium Chloride	85	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	82	15
Pantoprazole Sodium	Pantoprazole Sodium	81	27
Furosemide	Furosemide	79	18
Alendronate Sodium	Alendronate Sodium	71	22
Jardiance	Empagliflozin	71	21
Metformin Hcl	Metformin Hcl	71	26
Mirtazapine	Mirtazapine	67	16
Doxycycline Hyclate	Doxycycline Hyclate	63	49
Celecoxib	Celecoxib	62	23
Escitalopram Oxalate	Escitalopram Oxalate	62	18
Montelukast Sodium	Montelukast Sodium	59	20
Tamsulosin Hcl	Tamsulosin Hcl	58	24
Pravastatin Sodium	Pravastatin Sodium	56	21
Allopurinol	Allopurinol	55	15
Memantine Hcl	Memantine Hcl	54	suppressed
Fluticasone Propionate	Fluticasone Propionate	53	22
Torsemide	Torsemide	53	18
Donepezil Hcl	Donepezil Hcl	51	12
Prednisone	Prednisone	51	41
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	48	20
Methocarbamol	Methocarbamol	47	18
Simvastatin	Simvastatin	45	12
Albuterol Sulfate Hfa	Albuterol Sulfate	44	20
Clonazepam	Clonazepam	44	suppressed
Valsartan	Valsartan	43	20
Diclofenac Sodium	Diclofenac Sodium	41	13
Ozempic	Semaglutide	41	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	40	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	40	14
Famotidine	Famotidine	39	18
Lorazepam	Lorazepam	39	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	38	34
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	13
Paroxetine Hcl	Paroxetine Hcl	37	suppressed
Alprazolam	Alprazolam	36	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	36	suppressed
Fentanyl	Fentanyl	34	suppressed
Metformin Hcl Er	Metformin Hcl	34	14
Meloxicam	Meloxicam	32	17
Ropinirole Hcl	Ropinirole Hcl	31	suppressed
Glimepiride	Glimepiride	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Azelastine Hcl	Azelastine Hcl	25	11
Metoprolol Tartrate	Metoprolol Tartrate	25	suppressed
Entresto	Sacubitril/Valsartan	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Atenolol	Atenolol	23	suppressed
Cefdinir	Cefdinir	22	13
Glipizide	Glipizide	22	suppressed
Irbesartan	Irbesartan	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	21	suppressed
Rybelsus	Semaglutide	21	suppressed
Vascepa	Icosapent Ethyl	21	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Methylprednisolone	Methylprednisolone	20	20
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Diazepam	Diazepam	19	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Novolog Flexpen	Insulin Aspart	19	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Azithromycin	Azithromycin	18	17
Mounjaro	Tirzepatide	18	suppressed
Movantik	Naloxegol Oxalate	18	suppressed
Levofloxacin	Levofloxacin	17	13
Mupirocin	Mupirocin	17	16
Estradiol	Estradiol	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Glipizide Er	Glipizide	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	13
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Cephalexin	Cephalexin	13	11
Cinacalcet Hcl	Cinacalcet Hcl	13	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Water	Water For Irrigation,sterile	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Bacitracin-Polymyxin	Bacitracin/Polymyxin B Sulfate	12	suppressed
Colestipol Hcl	Colestipol Hcl	12	suppressed
Droxidopa	Droxidopa	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Liothyronine Sodium	Liothyronine Sodium	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Amoxicillin	Amoxicillin	11	11
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error